Find the right fit for you - faster
Get tailored insights about working at Omeros in one quick step.
Omeros Snapshot
Omeros’ primary focus is the patient. Rather than developing “me-too” products, we’re tackling serious diseases and disorders to improve or save the lives of patients who are suffering. We partner with physicians, regulators, and patients to develop the most effective and safe drugs possible. Focusing on targets never before drugged and significant unmet medical needs, we have a track record of succeeding where others have not and remain unrelenting in our efforts to benefit patients everywhere.
True innovation requires the right people, and that’s what we have at Omeros – smart, hard-working and creative individuals who collaborate and drive to achieve what has not yet been done. We see strength in diversity – diversity in thought, expertise and experience.
We have taken a similar approach in structuring our company. While many biotechs pursue a single therapeutic area or scientific platform, we are strategically building a deep and diverse pipeline of first-in-class small-molecule and antibody therapeutics. The strength of our scientific discoveries and exclusive intellectual property positions enable our pipeline programs to target highly promising receptors and enzymes that others have not been able to develop.
Although cutting across a wide and diverse range of disorders and therapeutic indications – many with no approved treatment – all of our drugs on the market and in development target critical unmet needs to improve the lives of patients in meaningful ways.
We have taken a similar approach in structuring our company. While many biotechs pursue a single therapeutic area or scientific platform, we are strategically building a deep and diverse pipeline of first-in-class small-molecule and antibody therapeutics. The strength of our scientific discoveries and exclusive intellectual property positions enable our pipeline programs to target highly promising receptors and enzymes that others have not been able to develop.
Although cutting across a wide and diverse range of disorders and therapeutic indications – many with no approved treatment – all of our drugs on the market and in development target critical unmet needs to improve the lives of patients in meaningful ways.
